Literature DB >> 11260408

Intrarenal angiotensin and bradykinin peptide levels in the remnant kidney model of renal insufficiency.

F E Mackie1, D J Campbell, T W Meyer.   

Abstract

BACKGROUND: The remnant kidney model of renal failure is associated with normal or suppressed plasma renin and angiotensin (Ang) II levels when hypertension is established. However, the hypertension responds to angiotensin-converting enzyme (ACE) inhibition and Ang II receptor antagonism, suggesting a role for Ang II in the hypertensive process. Bradykinin (BK) is a potent vasoactive peptide that may also participate in this model.
METHODS: Ang II and BK peptides were measured in the ischemic peri-infarct portion and the intact portion of the remnant kidney at two, five, and seven weeks after surgery. Plasma Ang II, renin, angiotensinogen, and aldosterone levels were also measured.
RESULTS: Ang II levels in the peri-infarct portion were higher than in the intact portion at all time points and were higher than in sham-operated kidney at two weeks. Ang II levels in the intact portion were similar to the levels in kidneys of sham-operated rats at two and five weeks and were suppressed at seven weeks. BK levels were increased in the peri-infarct portion at all time points and in the intact portion at two and five weeks. Plasma Ang II and aldosterone levels were also elevated at two weeks.
CONCLUSIONS: Peri-infarct renal tissue Ang II levels and plasma Ang II and aldosterone levels increase transiently during the evolution of hypertension in the remnant kidney model. Sustained hypertension is associated with an increase in intrarenal BK levels but not with persistent increases in intrarenal or circulating Ang II levels.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11260408     DOI: 10.1046/j.1523-1755.2001.0590041458.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  11 in total

Review 1.  Hormonal Regulation of Renal Fibrosis.

Authors:  Polina A Abramicheva; Egor Y Plotnikov
Journal:  Life (Basel)       Date:  2022-05-16

2.  Regulation of oxygen utilization by angiotensin II in chronic kidney disease.

Authors:  Aihua Deng; Tong Tang; Prabhleen Singh; Chen Wang; Joe Satriano; Scott C Thomson; Roland C Blantz
Journal:  Kidney Int       Date:  2008-09-24       Impact factor: 10.612

3.  Unexpected effect of angiotensin AT1 receptor blockade on tubuloglomerular feedback in early subtotal nephrectomy.

Authors:  Prabhleen Singh; Aihua Deng; Roland C Blantz; Scott C Thomson
Journal:  Am J Physiol Renal Physiol       Date:  2009-02-11

4.  Renoprotective Effects of AVE0991, a Nonpeptide Mas Receptor Agonist, in Experimental Acute Renal Injury.

Authors:  Lívia Corrêa Barroso; Kátia Daniela Silveira; Cristiano Xavier Lima; Valdinéria Borges; Michael Bader; Milene Rachid; Robson Augusto Souza Santos; Danielle Gloria Souza; Ana Cristina Simões E Silva; Mauro Martins Teixeira
Journal:  Int J Hypertens       Date:  2012-01-29       Impact factor: 2.420

Review 5.  Renal ischemia/reperfusion injury; from pathophysiology to treatment.

Authors:  Maryam Malek; Mehdi Nematbakhsh
Journal:  J Renal Inj Prev       Date:  2015-06-01

6.  Increased Blood Pressure Variability Prior to Chronic Kidney Disease Exacerbates Renal Dysfunction in Rats.

Authors:  Frederico F C T Freitas; Gilberto Araujo; Marcella L Porto; Flavia P S Freitas; Jones B Graceli; Camille M Balarini; Elisardo C Vasquez; Silvana S Meyrelles; Agata L Gava
Journal:  Front Physiol       Date:  2016-09-23       Impact factor: 4.566

7.  Plasma renin activity: An early marker of progressive renal disease in posterior urethral valves.

Authors:  Minu Bajpai; Amit Singh
Journal:  J Indian Assoc Pediatr Surg       Date:  2013-10

8.  Decreased renal AT1 receptor binding in rats after subtotal nephrectomy: PET study with [(18)F]FPyKYNE-losartan.

Authors:  Basma Ismail; Robert A deKemp; Tayebeh Hadizad; Kumiko Mackasey; Rob S Beanlands; Jean N DaSilva
Journal:  EJNMMI Res       Date:  2016-06-23       Impact factor: 3.138

9.  Novel Variants of Angiotensin Converting Enzyme-2 of Shorter Molecular Size to Target the Kidney Renin Angiotensin System.

Authors:  Jan Wysocki; Arndt Schulze; Daniel Batlle
Journal:  Biomolecules       Date:  2019-12-17

Review 10.  An update on ACE2 amplification and its therapeutic potential.

Authors:  Alonso Marquez; Jan Wysocki; Jay Pandit; Daniel Batlle
Journal:  Acta Physiol (Oxf)       Date:  2020-06-17       Impact factor: 7.523

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.